

Christopher M. Cashman

Mr. Cashman is a co-founder of Protez Pharmaceuticals Inc. and most recently served as Director, President and CEO. Protez was acquired by Novartis in 2008. He has 30 years experience in the pharmaceutical industry including prior roles as President and CEO, Message Pharmaceuticals, and as Vice President, Sales and Marketing, for both Pfizer and SmithKline Beecham. Mr. Cashman currently serves on the board of directors of the Science Center, Noble Biomaterials and as non-executive chairman of JDP Therapeutics and MBF Therapeutics.